International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study

作者：Julia Brandts, Fotios Barkas, Dirk De Bacquer, Catriona Jennings, Guy De Backer, Kornelia Kotseva, Lars Rydén, Gregory Y.H. Lip, Iris Erlund, Sandra Ganly, Terhi Vihervaara, Agnieszka Adamska, Ana Abreu, Wael Almahmeed, Ade Meidian Ambari, Junbo Ge, Hosam Hasan‐Ali, Yong Huo, Piotr Jankowski, Rodney M Jimenez, Yongbo Li, Ahmad Syadi Mahmood Zuhdi, Abel Makubi, Amam Mbakwem, Lilian Mbau, José L. Estrada, Okechukwu S. Ogah, Elijah Ogola, Adalberto Quintero–Baiz, Mahmoud U. Sani, María Inés Sosa Liprandi, Jack Wei Chieh Tan, Miguel Urina‐Triana, Tee Joo Yeo, D. Wood, John W. McEvoy, Kausik K. Ray · 发表于：European Journal of Preventive Cardiology · 年份：2025 · DOI：10.1093/eurjpc/zwaf388 · 被引用次数：12 · 研究领域：Lipoproteins and Cardiovascular Health、Diabetes, Cardiovascular Risks, and Lipoproteins、Diabetes Treatment and Management

AIMS: To quantify international variations in lipid-lowering therapies (LLT) use among patients with coronary heart disease (CHD) and attainment of European guideline-recommended lipid goals. METHODS AND RESULTS: INTERASPIRE is an observational study (2020-23) covering 14 countries from all WHO regions. Patients (18-79 years) hospitalized in the preceding 6-36 months with CHD were invited for standardized interviews and examination, with central laboratory analyses for low-density lipoprotein cholesterol (LDL-C), non-HDL-C, and apolipoprotein B (apoB). Valid lipid data meeting quality control standards were available from 13 countries. Lipid goals followed the 2019 guidelines of the European Atherosclerosis Society and the European Society of Cardiology: LDL-C < 1.4 mmol/L, non-HDL-C < 2.2 mmol/L, and apoB <65 mg/dL.Among 4061 patients (78.8% male, mean age 60.3 years), between index event and interview, 66.3% had no change in treatment intensity. LLT use at interview was largely statin monotherapy: 49.6% high-intensity (inter-country range 5.3%-77.3%) and 24.1% low/moderate-intensity (inter-country range 5.1%-70.1%). Otherwise, 12.2% (inter-country range 0.2%-41.1%) were on combination therapy, and 12.7% on no LLT (inter-country range 3.5%-36.7%). Goal attainment for LDL-C was 17.5%. Corresponding non-HDL-C and apoB goals were achieved by 29.9% and 29.2%, respectively. Higher-income countries (defined by the World Bank's 2024-25 classification of income levels) did better in...